Innovent’s Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study
ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced second interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study (NCT03802240) conducted in China evaluating sintilimab with...
InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer
NANJING, China, Sept. 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study evaluating IN10018, a highly potent and selective oral inhibitor of focal...
Global study shows Artificial Intelligence can reduce time to pregnancy for IVF couples by 12%
SAN FRANCISCO, Sept. 7, 2022 /PRNewswire/ -- Reproductive BioMedicine Online (RBMO) journal has published results of an international clinical study BY Presagen showing that its Artificial Intelligence (AI) product Life Whisperer can reduce time to pregnancy for IVF couples by 12%, potentially saving costs and heartbreak associated with failed cycles. The study was conducted with IVF clinics globally, including...
Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board
NEWARK, Del., Sept. 7, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global R&D biotechnology company, today announced the appointment of Rakesh Dixit, Ph.D., DABT to its Advisory Board to advance Antibody Drug-Conjugates (ADCs) for the treatment of solid tumor cancers in Biosion's pipeline. Dr. Dixit is a highly accomplished leader and scientist as evidenced by being awarded the...
Pulnovo Medical Limited’s PADN Technology Included in 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH
SHANGHAI, Sept. 7, 2022 /PRNewswire/ -- A globally recognized OTM innovative platform Pulnovo Medical Limited's proprietary Pulmonary Artery Denervation (PADN) technology has been included in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of pulmonary arterial hypertension (PAH) (hereinafter referred to as "the Guidelines"), jointly issued by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),...
Lianhua Products Designated as Epidemic Prevention Supplies : 2022 CIFTIS
SHIJIAZHUANG, China, Sept. 7, 2022 /PRNewswire/ -- The 2022 China International Fair for Trade in Services (CIFTIS), which opened on August 31, 2022, in Beijing, is the only annual international and comprehensive platform for trade in services in the world. Yiling Pharmaceutical's Lianhua respiratory health products, the well-known anti-epidemic star products, were again designated as the epidemic prevention supplies by...
Tycoon Group Signs Cooperation Agreement with JD Logistics, Obtains Operating Rights of Logistics Supply Chain Industry Bases in France
The commence of business operation in France is a step forward to enter European markets, optimising the Group's portfolio and increasing its sources of revenue. HONG KONG, Sept. 7, 2022 /PRNewswire/ -- Tycoon Group Holdings Limited ("Tycoon Group" or the "Group", Stock Code: 3390.HK), an omnichannel brand marketing and management service integrator of health and well-being related products in Hong...
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting
SHANGHAI and PARIS, Sept. 7, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH018 (TGF-β R1 inhibitor) monotherapy (NCT05051241) for treatment of advanced solid tumor will be presented as a poster at the 2022 European Society for Medical Oncology Meeting in...
Waterdrop Announces Appointment of a New Director
BEIJING, Sept. 7, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Ms. Wenjie Guan as a new director to its board of directors (the "Board"), effective September 7, 2022. After the change, the Board will...
TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action
VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by...
